Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Concizumab - Novo Nordisk

Next Previous
Search
Drug Profile

Concizumab - Novo Nordisk

Alternative Names: ALHEMO; Alhemo; Anti-TFPI monoclonal antibody; mAb-2021; NN-7415; NNC-0172-0000-2021; NNC-0172-2021; NNC-172-2021

Latest Information Update: 26 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Class Antihaemorrhagics; Monoclonal antibodies
  • Mechanism of Action Lipoprotein-associated coagulation inhibitor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B; Haemophilia A
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Haemophilia A; Haemophilia B
  • Phase II Haemophilia

Most Recent Events

  • 20 Dec 2024 Registered for Haemophilia A (In adolescents, In adults, Prevention) in USA (SC)
  • 20 Dec 2024 Registered for Haemophilia B (In adolescents, In adults, Prevention) in USA (SC)
  • 07 Dec 2024 Updated efficacy and adverse events data from the phase III explorer7 and explorer8 trials in Haemophilia A and B presented at 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top